Ajay D Rao

Dr. Ajay D Rao

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2008 in Diabetes Care
Verified
Journal Article
Open access
ARAjay D Rao
Ajay D Rao
NKNitesh Kuhadiya
Nitesh Kuhadiya
KRKristi Reynolds
Kristi Reynolds
VFVivian A. Fonseca
Vivian A. Fonseca
OBJECTIVE—Observational studies assessing the association of combination therapy of metformin and sulfonylurea on all-cause and/or cardiovascular mortality in type 2 diabetes have shown conflicting results. We therefore evaluated the effects of combination therapy of sulfonylureas and metformin on the risk of all-cause mortality and cardiovascular disease (CVD) among people with type 2 diabetes. RESEARCH DESIGN AND METHODS—A MEDLINE search (January 1966–July 2007) was conducted to identify observational studies that examined the association between combination therapy of sulfonylureas and metformin on risk of CVD or all-cause mortality. From 299 relevant reports, 9 were included in the meta-analysis. In these studies, combination therapy of metformin and sulfonylurea was assessed, the risk of CVD and/or mortality was reported, and adjusted relative risk (RR) or equivalent (hazard ratio and odds ratio) and corresponding variance or equivalent was reported. RESULTS—The pooled RRs (95% CIs) of outcomes for individuals with type 2 diabetes prescribed combination therapy of sulfonylureas and metformin were 1.19 (0.88–1.62) for all-cause mortality, 1.29 (0.73–2.27) for CVD mortality, and 1.43 (1.10–1.85) for a composite end point of CVD hospitalizations or mortality (fatal or nonfatal events). CONCLUSIONS—The combination therapy of metformin and sulfonylurea significantly increased the RR of the composite end point of cardiovascular hospitalization or mortality (fatal and nonfatal events) irrespective of the reference group (diet therapy, metformin monotherapy, or sulfonylurea monotherapy); however, there were no significant effects of this combination therapy on either CVD mortality or all-cause mortality alone.

1 June 2010 in Endocrinology and Metabolism Clinics of North America
Verified
Journal Article
Closed access
ABArti Bhan
Arti Bhan
ARAjay D Rao
Ajay D Rao
DRD. Sudhaker Rao
D. Sudhaker Rao

14 August 2014 in Diabetes
Verified
Journal Article
Open access
RGRajesh Garg
Rajesh Garg
ARAjay D Rao
Ajay D Rao
MBMaria Baimas-George
Maria Baimas-George
SHShelley Hurwitz
Shelley Hurwitz
CFCourtney Foster
Courtney Foster
GAGail K. Adler
Gail K. Adler
Reduced coronary flow reserve (CFR), an indicator of coronary microvascular dysfunction, is seen in type 2 diabetes mellitus (T2DM) and predicts cardiac mortality. Since aldosterone plays a key role in vascular injury, the aim of this study was to determine whether mineralocorticoid receptor (MR) blockade improves CFR in individuals with T2DM. Sixty-four men and women with well-controlled diabetes on chronic ACE inhibition (enalapril 20 mg/day) were randomized to add-on therapy of spironolactone 25 mg, hydrochlorothiazide (HCTZ) 12.5 mg, or placebo for 6 months. CFR was assessed by cardiac positron emission tomography at baseline and at the end of treatment. There were significant and similar decreases in systolic blood pressure with spironolactone and HCTZ but not with placebo. CFR improved with treatment in the spironolactone group as compared with the HCTZ group and with the combined HCTZ and placebo groups. The increase in CFR with spironolactone remained significant after controlling for baseline CFR, change in BMI, race, and statin use. Treatment with spironolactone improved coronary microvascular function, raising the possibility that MR blockade could have beneficial effects in preventing cardiovascular disease in patients with T2DM.

31 May 2012 in Journal of Human Hypertension
Verified
Journal Article
Open access
PDF file
ARAjay D Rao
Ajay D Rao
BSB Sun
B Sun
ASA Saxena
A Saxena
PHP N Hopkins
P N Hopkins
XJX Jeunemaitre
X Jeunemaitre
JWJ S Williams
J S Williams
Serum- and glucocorticoid-inducible kinase 1 (SGK1) has a central role in epithelial sodium channel (ENaC)-dependent Na+ transport in the distal nephron. We hypothesized that SGK1 gene variants may contribute to the effect of dietary salt intake on blood pressure (BP) in humans with hypertension, and consequentially influence renin–angiotensin–aldosterone (RAA) system activity. Our study population included 421 hypertensive Caucasian participants of the HyperPath group who had completed a dietary salt protocol with measurement of BP and RAA system activity. Three SGK1 tagging single nucleotide polymorphisms (SNPs) from the HapMap CEU population captured the genetic variation in the SGK1 region. Assuming an additive genetic model, two SNPs (rs2758151 and rs9402571) were associated with BP and plasma renin activity (PRA) effects of dietary salt intake. Major alleles were associated with higher systolic BP on high salt and decreased PRA on low salt. In contrast, low salt neutralized genotype differences. Similar, non-significant trends were observed in a normotensive population (N=152). Genotype was also associated with two salt-sensitive subtypes of hypertension. SGK1 genetic variants are associated with salt sensitivity of BP and PRA in human hypertension. Genotype status at these SGK1 variants may identify individuals prone to salt-sensitive hypertension.

1 March 2010 in Journal of Diabetes and its Complications
Verified
Journal Article
Closed access
TTTina K. Thethi
Tina K. Thethi
ARAjay D Rao
Ajay D Rao
HKHaytham Kawji
Haytham Kawji
TMTilak Mallik
Tilak Mallik
CYC. Lillian Yau
C. Lillian Yau
VFVivian Fonseca
Vivian Fonseca

1 January 2000 in Journal of Clinical Densitometry
Verified
Journal Article
Closed access
ARAjay D Rao
Ajay D Rao
SRSushma Reddy
Sushma Reddy
DRD. Sudhaker Rao
D. Sudhaker Rao